Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Leases (2023 - 2025)

Kura Oncology (KURA) has disclosed Current Leases for 3 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases fell 32.11% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 32.11% decrease, with the full-year FY2025 number at $1.3 million, down 32.11% from a year prior.
  • Current Leases was $1.3 million for Q4 2025 at Kura Oncology, down from $1.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.3 million in Q2 2023 to a low of $1.3 million in Q4 2025.
  • A 3-year average of $1.7 million and a median of $1.7 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: crashed 41.55% in 2024, then skyrocketed 39.77% in 2025.
  • Kura Oncology's Current Leases stood at $1.5 million in 2023, then grew by 24.9% to $1.9 million in 2024, then crashed by 32.11% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Current Leases are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.7 million (Q2 2025).